Botox vs. Jeuveau for Men: What's the Difference and Which Should You Choose?

The injectable neuromodulator market now includes four FDA-approved options — Botox (Allergan/AbbVie), Dysport (Galderma), Xeomin (Merz), and Jeuveau (Evolus). Jeuveau, launched in 2019 and marketed heavily as a 'next-generation' alternative to Botox, has generated more questions than any of the other alternatives. Men searching for Botox increasingly encounter Jeuveau at med spas offering it at lower prices and with aggressive marketing. Understanding what Jeuveau actually is — and isn't — lets you evaluate whether the savings are meaningful or just noise.

What Is Jeuveau?

Jeuveau is botulinum toxin type A produced by Daewoong Pharmaceutical (South Korea) and marketed in the US by Evolus under the brand name Jeuveau, sometimes called 'Newtox' in marketing materials. It is FDA-approved specifically for the temporary improvement of moderate-to-severe glabellar lines (frown lines between the brows) in adults. Like Botox, it works by blocking acetylcholine release at the neuromuscular junction, relaxing the target muscle and softening the overlying expression lines. At the mechanism-of-action level, Jeuveau and Botox work identically — they are the same molecule (botulinum toxin type A) produced through different manufacturing processes.

Clinical Differences: Is There a Meaningful Distinction?

Head-to-head clinical trials comparing Jeuveau to Botox show comparable efficacy and duration for glabellar line treatment. Both products have similar onset times (3–7 days for initial effect, 10–14 days for full effect), similar duration of action (3–4 months), and similar side effect profiles. Some providers and patients report subjective differences in 'feel' or onset characteristics, but these observations are not supported by robust clinical evidence and likely reflect inter-patient variability and nocebo/placebo effects. The honest clinical answer is: for frown line treatment, Jeuveau and Botox are equivalent.

The Real Difference: Price

Jeuveau was positioned as a price-competitive alternative to Botox, and it has generally succeeded at this positioning. Practices that offer Jeuveau typically price it $2–5 per unit less than Botox, and some med spas offer Jeuveau promotional pricing specifically to attract cost-conscious patients. For a typical male treatment of 50–80 units, this represents a savings of $100–400 per session. Over a year of regular treatment (3 sessions), the savings can reach $300–1,200. This is a meaningful difference — as long as the lower price is from competitive manufacturing economics and not from provider quality or dosing shortcuts.

Which Should You Choose?

If you're choosing between Jeuveau and Botox with an equally skilled provider who doses appropriately for male anatomy, Jeuveau is a reasonable choice if the price is lower. If the choice is between Jeuveau at a lower-quality or lower-skill practice versus Botox with an experienced, male-focused provider, pay for the better provider regardless of which product they use. The product is not the variable that determines whether you get a great result — the injector is. Both Jeuveau and Botox in the hands of an expert who understands male facial aesthetics will produce excellent results. Both in the hands of an under-trained injector will produce mediocre ones. Find expert providers near you at /find-botox-near-me.

What About Dysport and Xeomin?

Dysport (abobotulinumtoxinA) has a larger protein complex than Botox, spreads more widely from the injection site, and requires a different unit conversion (approximately 2.5–3 Dysport units = 1 Botox unit). It's established with good clinical data and is favored by some providers for specific areas. Xeomin (incobotulinumtoxinA) is a 'naked' neurotoxin — it lacks the accessory proteins found in Botox and Dysport — which theoretically reduces antibody formation with repeat treatment. All four products are legitimate options in skilled hands.